Investors

Home / Investors / Overview

Company Information

CymaBay Therapeutics (Nasdaq: CBAY)

We are a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need. We are evaluating seladelpar in primary biliary cholangitis (PBC). We also have a product program in earlier development that features a unique mechanism of action with potential in chronic diseases.

Stock Information


Last Change Volume

Shares Outstanding: 10,064,495
(as of March 3, 2014)

Company Information

CymaBay Therapeutics
7575 Gateway Blvd
Suite 110
Newark, CA 94560

Investor Relations

LifeSci Advisors, LLC
Hans Vitzthum
(617) 430-7578
Hans@LifeSciAdvisors.com

Recent News

23May

CymaBay Therapeutics Presents New Findings that Seladelpar Treatment of PBC Patients for Two Years Predicts Improved Transplant-Free Survival

12May

CymaBay Reports First Quarter 2022 Financial Results and Provides Corporate Update

11May

CymaBay Therapeutics Announces Presentations at Digestive Disease Week® 2022

Upcoming Event

Jun 9 2022 8:00am PT

Annual Meeting of Stockholders

June 9, 2022 at 8:00am PT

Q1 2022 Quarterly Results